RLYP News
Archived Headlines
- 12 US IPOs planned for the week of Nov 11 11/11/13
- Late-stage biotech Relypsa sets terms for $120 million IPO 11/01/13
- Late-stage biotech Relypsa raises deal size to $138 million 10/17/13
- US IPO Recap: Foundation Medicine soars, Chrysler revs up for an IPO 09/30/13
- Late-stage biotech Relypsa files for a $127 million IPO 09/27/13
Biotech IPOs are back to normal
By almost any measure, 2013 has been a record-breaking year for biotech IPOs. The 33 biotech IPOs completed and the $2.5 billion raised are more than the totals from the previous five years combined and far exceed the levels reached at the height of the tech...read more
US IPO Recap: IPO count rises above 200
Last week, IPO issuers were challenged by investor selectivity and pricing discipline. Half of the week’s eight deals were priced below the range, and three early-stage health care companies postponed their IPOs. Online textbook rental company Chegg...read more
Relypsa prices IPO at $11, below expectations
Relypsa, a late-stage biotech developing a treatment for hyperkalemia, raised $75 million by offering 6.9 million shares at $11, below the expected price of $12. Relypsa plans to list on the NASDAQ under the symbol RLYP. Relypsa initially filed confidentially on...read more
Relypsa decreases proposed IPO price to $12, deal size is now $82 million
Relypsa, a late-stage biotech developing a treatment for hyperkalemia, lowered the proposed deal size for its upcoming IPO on Thursday. The Redwood City, CA-based company now plans to raise $82 million by offering 6.9 million shares at $12 per share. The company...read more